Willow Biosciences Inc - CANSF STOCK NEWS

Welcome to our dedicated news page for Willow Biosciences (Ticker: CANSF), a resource for investors and traders seeking the latest updates and insights on Willow Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Willow Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Willow Biosciences's position in the market.

03/28/2024 07:30 PM

News

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Rhea-AI Summary

Willow Biosciences Inc. reports a record revenue of $1.2 million in 2023, representing a 43% growth over 2022. The company completed a reorganization, moved all lab operations to Sunnyvale, California, and signed four new partnerships positioning it for growth in 2024. Willow's financial results show a net loss of $13.0 million in 2023, with cash and cash equivalents at $3.1 million as of December 31, 2023. The company anticipates significant revenue growth in 2024 with the transition of R&D programs to commercial revenue and the execution of partnership agreements on corticosteroid programs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.13%

Tags

02/29/2024 06:00 PM

News

WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC

Rhea-AI Summary

Willow Biosciences Inc. secures a second strategic investment from Kalsec Inc. for the development of natural food ingredients, achieving a significant milestone. The investment will aid in commercializing the company's product pipeline and supporting general corporate activities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/20/2024 06:00 PM

News

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Rhea-AI Summary

Willow Biosciences Inc. receives a strategic investment from Kalsec Inc. to accelerate the development of natural food ingredients. The investment of US$100,000 will support the commercialization of Willow's product pipeline, including natural food ingredients, working capital, and general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-9%

Tags

01/31/2024 07:00 AM

News

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Rhea-AI Summary

Willow Biosciences Inc. announced a collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. The partnership program will focus on optimizing an existing commercial biomanufacturing process for improved performance at scale. The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments for achieving defined performance targets. Willow's President & CEO, Dr. Chris Savile, expressed excitement about the potential impact on human health and the value to the partner and shareholders. This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.41%

Tags

01/16/2024 07:00 AM

News

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Rhea-AI Summary

Willow Biosciences Inc. announced a collaboration with Enterin, Inc. to develop sustainable manufacturing routes for key intermediates and active pharmaceutical ingredients. The collaboration is expected to last approximately three months and represents the 3rd development agreement with companies seeking access to Willow's transformative BioOxiTM selective hydroxylation platform.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12.5%

Tags

01/10/2024 07:00 AM

News

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Rhea-AI Summary

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) achieved record revenues of approximately $1.3 million in 2023, representing a 60% increase from the previous year. The company launched the BioOxi bio-oxidation platform technology, strengthened its portfolio of partnered and proprietary programs, and underwent successful corporate and operational reorganization. In 2024, Willow anticipates significant revenue growth, execution of commercial agreements, and the closing of new partnership agreements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.3%

Tags

12/07/2023 07:00 AM

News

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Rhea-AI Summary

Willow Biosciences Inc. (WLLW) announces a program with a Nasdaq-listed biopharma company to develop manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients. The program is expected to bring immediate R&D revenue and first commercial supply revenue as early as 2024, validating Willow's BioOxi™ technology and strategic focus on near-term revenue generation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.19%

Tags

11/14/2023 06:06 PM

News

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Rhea-AI Summary

Willow Biosciences Inc. (WLLW) reports record revenues for the third quarter and the nine months ended September 30, 2023. They also filed a patent application for a process to produce corticosteroids at a significant cost reduction and signed two new program agreements, advancing three programs to the next phase of development. The company's financial and operating results show significant progress in sustainable business growth and commercial expansion.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/10/2023 07:52 PM

News

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING

Rhea-AI Summary

Willow Biosciences completes convertible debenture offering for C$800,000

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/03/2023 07:00 AM

News

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Rhea-AI Summary

Willow Biosciences and SUANFARMA collaborate on a cell line productivity optimization program for manufacturing anti-infective API through precision fermentation. SUANFARMA will use Willow's strain optimization technologies to develop a more cost-effective production process. The partnership aims to create alternative means for sustainable production. This collaboration marks progress in broadening the relationship and expanding the joint product portfolio. Willow develops and produces precision fermented functional ingredients for various markets. SUANFARMA is a B2B life science partner specialized in the development, production, and commercialization of ingredients. No specific financial figures or percentages are mentioned in the PR.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.06%

Tags